Ronald Dorenbos – Biomedical Science Associate Navigator, Director of Global Business Development

Spotlight: Dr. Ronald Dorenbos is an accomplished international Project Leader in the Biotech and Pharmaceutical Industry who has worked with different companies and institutes throughout Europe and the US such as Harvard, Genencor, and Novo Nordisk. Dr. Dorenbos brings his wealth of life science expertise and experience to our Biomedical Science Core as well as lending his multidisciplinary project management experience toward supporting the company’s business development efforts through directly contributing to global e-marketing efforts that serve to improve the visibility of the company world wide.

Dr. Dorenbos also currently serves as a project leader at RXi Pharmaceuticals leading a collaboration with the neurology department at the University of Massachusetts Medical School to develop RNAi-based therapeutics for Lou Gehrig’s Disease. Dr. Dorenbos has a versatile background in areas such as project management, business development, R&D, consulting, and marketing and has worked in the Netherlands, the UK, Italy, and the United States.

Interesting: Dr. Dorenbos is originally from the Netherlands, speaks multiple languages, has authored (or co-authored) 8 research publications as well as a book chapter, and has been a featured scientific presenter at meetings and conferences for such prestigious organizations as the Society for Neuroscience, the Association for Research in Vision and Ophthalmology, and the European Bacillus Secretion Group. Additionally, Dr. Dorenbos was a member of the life science and networking panels at the Boston Seminar organized by the Dutch Government.

Apart from science, another passion of Dr. Dorenbos is music. He plays the clarinet and several other instruments and manages the Clarinet LinkedIn Group that has members from all over the world.

Background: Dr. Dorenbos started his professional education in chemistry, but soon switched to biotechnology, recognizing the growth and potential of this field. He started this study in the Netherlands, and finished it in the UK at the De Montfort University in Leicester. Upon his return to the Netherlands he continued with Molecular Biology and subsequently did his Ph.D. in the Netherlands at the University of Groningen, studying disulfide bond formation in proteins in Bacillus subtilis.

Realizing that he wanted to work on challenges more closely related to human health he decided to make a career change and accepted a position at the neurobiology department of Harvard Medical School to perform research related to Parkinson’s disease. This led to his current position at RXi Pharmaceuticals. Recognizing the importance of bringing developments from the lab to the patient, Dr. Dorenbos joined forces with Munevar & Associates, Inc. to contribute towards its mission of bridging bench to bedside.

  • PhD, Moleculary Biology, University Medical Center Groningen, Netherlands
  • MSc, Molecular Biology, University of Groningen, Netherlands
  • MSc, Biotechnology, Technical University Groningen, Netherlands / De Montfort University, Leicester, UK
  • BSc, Chemistry, Laboratory Education (MLO) Groningen, Netherlands, Bachelor’s degree in Chemistry

Comments are closed.